Reason: Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL).
Distributed: Nationwide in the USAReason: CGMP deviations: Out of specification results obtained during routine stability testing for ethanol content.
Distributed: Nationwide and Puerto RicoReason: Presence of Particulate Matter: A complaint was received for the presence of a single strand of hair in one vial.
Distributed: Nationwide in the USAReason: Superpotent Drug: Out of specification for assay at the 12-month timepoint.
Distributed: Nationwide in the USAReason: Superpotent Drug: Out of specification for assay at the 12-month timepoint.
Distributed: Nationwide in the USAReason: Product mix-up:0.2 mg strength Clonidine Hydrochloride Tablets, USP in a 100-count bottle of 0.3 mg strength Clonidine Hydrochloride Tablets,
Distributed: Distributed Nationwide in the USAReason: Presence of particulate matter
Distributed: USA NationwideReason: Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product.
Distributed: Nationwide in the US.Reason: Presence of Foreign Substance: Foreign material (metal piece) embedded in one tablet.
Distributed: Distributed to two direct accounts in PA and AK.Reason: CGMP Deviations: FDA analysis found product to contain acetaldehyde impurity and the Sum of All Impurities, above specification limits.
Distributed: Nationwide in the US.